21 November 2017
News and Views
Links and Services
Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease, finds the most recent issue of the American Journal of Gastroenterology.
Arbaclofen placarbil, previously designated as XP19986, is an investigational prodrug of the acti
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors